Equities

TFF Pharmaceuticals Inc

TFF Pharmaceuticals Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)2.67
  • Today's Change-0.06 / -2.20%
  • Shares traded46.90k
  • 1 Year change-82.12%
  • Beta1.4327
Data delayed at least 15 minutes, as of May 01 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

TFF Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaging patented rapid freezing technology to develop and transform medicine into potent dry powder. It is focused on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform. Its TFF technology platform has an applicability to convert any drug, including vaccines, small and large molecules, and biologics, into a dry powder for inhalation, or for topical delivery to the eyes, nose and the skin. TFF Pharmaceuticals has two lead drug candidates in the clinic: TFF TAC (Tacrolimus Inhalation Powder) and TFF VORI (Voriconazole Inhalation Powder). TFF TAC is an inhaled dry powder formulation of tacrolimus, for the prophylaxis of organ rejection in patients receiving lung transplants, in combination with other immunosuppressants. TFF VORI is an inhaled dry powder formulation of voriconazole, for the treatment and prophylaxis of invasive pulmonary aspergillosis.

  • Revenue in USD (TTM)733.87k
  • Net income in USD-21.24m
  • Incorporated2018
  • Employees19.00
  • Location
    TFF Pharmaceuticals Inc2600 Via Fortuna Ste 360AUSTIN 78746-7983United StatesUSA
  • Fax+1 (302) 655-5049
  • Websitehttps://tffpharma.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Stemtech Corp4.64m-4.08m6.46m45.00------1.39-0.0624-0.06240.0619-0.00921.098.3565.16103,098.40-96.70------76.09---88.58--0.1045-1.812.27--------------
Azitra Inc686.00k-12.64m6.47m10.00--0.9331--9.43-2.99-2.990.07130.24080.1117--4.8868,600.00-183.73---266.83-------1,644.87-----45.860.0138--141.55--6.02------
Lixte Biotechnology Holdings Inc0.00-5.09m6.48m3.00--13.09-----2.77-2.770.001.780.00----0.00-103.09-104.18-111.07-111.05------------0.00------19.41------
Cell MedX Corp70.00-96.91k6.54m0.00------93,417.15-0.0029-0.00290.00-0.00240.0015-------202.28-792.55-----685.71---138,442.90-3,681.84---3.17-----54.53--29.01------
Scorpius Holdings Inc2.23m-46.05m6.62m77.00--0.1321--2.97-1.78-2.000.08591.390.0234--0.676228,918.57-50.05-38.42-61.25-42.0629.10---2,136.28-703.02----0.2305--202.1233.24-23.85--218.50--
TFF Pharmaceuticals Inc733.87k-21.24m6.73m19.00--0.6614--9.17-12.67-12.670.40974.040.0406--2.3738,624.74-117.54-79.57-130.37-83.41-----2,894.69-8,687.66----0.00--48.01--33.13------
Theralink Technologies Inc635.46k-13.50m6.77m16.00------10.65-0.0027-0.00270.00006-0.00930.2525--13.5139,716.25-536.39------73.50---2,124.10-----1.35----6.85---138.38------
Enveric Biosciences Inc0.00-17.46m6.78m7.00--1.30-----8.15-8.150.000.71420.00----0.00-144.99-104.94-207.98-156.88-------243.54----0.00------7.14------
Calidi Biotherapeutics Inc0.00-28.74m6.90m38.00---------0.6324-0.63240.00-0.02410.00----0.00-284.51-----------------25.251.25---89.98---132.57------
Pulmatrix Inc7.30m-14.12m6.90m22.00--0.3836--0.9459-3.87-3.872.004.930.1948--6.56331,727.30-37.70-46.91-42.80-58.12-----193.49-238.04----0.00--20.21116.6225.03--104.29--
MyMD Pharmaceuticals Inc0.00-7.07m6.90m9.00--0.3264-----5.53-5.530.0010.280.00----0.00-25.59-76.20-31.13-84.38--7.64---4,290.96----0.00------49.15------
Theriva Biologics Inc0.00-18.35m6.96m21.00--0.1884-----1.15-1.150.002.310.00----0.00-28.88-36.95-32.40-40.16------------0.0056------8.37--95.91--
AiXin Life International Inc4.09m-2.09m7.00m207.00------1.71-0.0836-0.08360.1636-0.07650.82685.4310.0219,757.49-42.27-16.93---34.5416.2548.13-51.12-36.960.1515------51.0058.0867.18--194.59--
Trevena Inc3.13m-40.29m7.03m23.00------2.25-3.16-3.160.2611-0.44290.073.69--135,869.60-90.25-55.93-110.38-66.3546.56---1,289.25-3,134.414.66-15.431.33--847.61-11.4324.93---24.67--
CV Sciences Inc16.00m3.10m7.05m42.002.092.412.110.44060.02060.02060.1040.0181.461.4626.74381,047.6028.28-43.42247.47-77.7544.2751.8119.38-45.680.373313.680.0805---1.24-19.80133.96-20.87----
Data as of May 01 2024. Currency figures normalised to TFF Pharmaceuticals Inc's reporting currency: US Dollar USD

Institutional shareholders

15.02%Per cent of shares held by top holders
HolderShares% Held
Carlson Capital LPas of 31 Dec 2023193.96k7.70%
DRW Securities LLCas of 31 Dec 202340.00k1.59%
Westside Investment Management LLCas of 31 Mar 202439.23k1.56%
The Vanguard Group, Inc.as of 31 Dec 202333.50k1.33%
AIGH Capital Management LLCas of 31 Dec 202329.48k1.17%
Geode Capital Management LLCas of 31 Dec 202315.72k0.62%
Renaissance Technologies LLCas of 31 Dec 202311.50k0.46%
BlackRock Fund Advisorsas of 31 Dec 20238.53k0.34%
Allianz Spravcovska Spolocnost ASas of 31 Dec 20224.66k0.19%
UBS Financial Services, Inc.as of 31 Dec 20231.74k0.07%
More ▼
Data from 30 Jun 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.